L R Duska - JoVE Visualize

Showing results (11-20 of 24) with videos related to

Pageof 3

Sort By:

Obstetrics and Gynecology|February 20, 1998

Clinical evaluation of atypical glandular cells of undetermined significance on cervical cytologyL R Duska, C F Flynn, A Chen, et al.

Gynecologic Oncology|October 19, 2001

Endometrial cancer in women 40 years old or youngerL R Duska, A Garrett, B R Rueda, et al.

Gynecologic Oncology|August 7, 2004

BAG-1 expression in normal and neoplastic endometriumT Moriyama, R D Littell, R Debernardo, et al.

Cancer|June 22, 1999

Epithelial ovarian carcinoma in the reproductive age groupL R Duska, Y C Chang, C E Flynn, et al.

Cancer|October 3, 2000

A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomographyR E Bristow, L R Duska, N C Lambrou, et al.

Gynecologic Oncology|June 15, 1999

Predictors of recurrence in surgical stage II endometrial adenocarcinomaC M Feltmate, L R Duska, Y Chang, et al.

Gynecologic Oncology|April 6, 2020

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaL R Duska, G R Petroni, N Varhegyi, et al.

Gynecologic Oncology|June 30, 2006

Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimenU A Matulonis, S Campos, C N Krasner, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 1999

A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancerL R Duska, R Penson, J G Supko, et al.

Gynecologic Oncology|September 23, 2017

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancerG Rustin, I Vergote, J P Micha, et al.

Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:

Pageof 3

Obstetrics and Gynecology|February 20, 1998

Clinical evaluation of atypical glandular cells of undetermined significance on cervical cytologyL R Duska, C F Flynn, A Chen, et al.

Gynecologic Oncology|October 19, 2001

Endometrial cancer in women 40 years old or youngerL R Duska, A Garrett, B R Rueda, et al.

Gynecologic Oncology|August 7, 2004

BAG-1 expression in normal and neoplastic endometriumT Moriyama, R D Littell, R Debernardo, et al.

Cancer|June 22, 1999

Epithelial ovarian carcinoma in the reproductive age groupL R Duska, Y C Chang, C E Flynn, et al.

Cancer|October 3, 2000

A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomographyR E Bristow, L R Duska, N C Lambrou, et al.

Gynecologic Oncology|June 15, 1999

Predictors of recurrence in surgical stage II endometrial adenocarcinomaC M Feltmate, L R Duska, Y Chang, et al.

Gynecologic Oncology|April 6, 2020

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaL R Duska, G R Petroni, N Varhegyi, et al.

Gynecologic Oncology|June 30, 2006

Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimenU A Matulonis, S Campos, C N Krasner, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 1999

A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancerL R Duska, R Penson, J G Supko, et al.

Gynecologic Oncology|September 23, 2017

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancerG Rustin, I Vergote, J P Micha, et al.

Pageof 3